Thursday, October 29, 2015
SRI International has been awarded a resource contract of up to $100 million over five years by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, for the development of products to mitigate or treat acute or delayed effects of radiation exposure. Under the multiyear contract, SRI Biosciences, a division of SRI International, will provide services, facilities, expertise and capabilities to advance the development of radiation/nuclear medical countermeasure therapies from early-stage discovery toward licensure or approval by the FDA.
After the early success of Immune Checkpoint Inhibitors, T-cell immunotherapy has emerged as another innovative and potent arm of the immuno-oncology market. Characterized by features such as target specificity, adaptability and memory, T-cells have been effectively used as tools to mediate an immune response. According to a recent report by Roots Analysis, there are close to 180 therapies across various phases of development.
In an effort to accelerate timelines and decrease development costs of life-saving vaccines, the Infectious Disease Research Institute (IDRI) and Sanofi Pasteur have established the Global Health Vaccine Center of Innovation (GHVCI), to be based at IDRI in Seattle. The project is funded in part by a grant from the Bill & Melinda Gates Foundation. The GHVCI represents an alliance among the three organizations, focused on accelerating the development of vaccines and associated technologies to fight a wide range of global infectious diseases, and ensuring that those critical vaccines are accessible globally, especially to people in need within developing countries.
The Dementia Discovery Fund, a new initiative designed to speed up the discovery and development of new treatments for dementia, has launched after securing $100 million backing from worldwide investors. The U.K. government’s Department of Health, Alzheimer’s Research U.K. and pharmaceutical companies including Biogen, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Pfizer and Takeda have joined forces to support the innovative new fund.
Germany-based Grünenthal, Denmark-based Nordic Bioscience and U.K.-based Argenta Discovery 2009, a Charles River company, are collaborating to improve the R&D of therapeutic approaches in multi-organ fibrosis. With a particular focus on fast-progressing patient subpopulations, the collaboration aims to develop new and improved preclinical and clinical assays to optimize the identification of new therapies.